老板办公室乳摸GIF动态图,色婷婷亚洲一区二区三区,国产全是老熟女太爽了,欧美极度残忍变态另类电影

更用心，只為更好地護(hù)佑健康

我們將對患者的關(guān)懷體現(xiàn)在藥物生產(chǎn)和運轉(zhuǎn)的全過程細(xì)節(jié)把控中
Inhixa
通用名：
依諾肝素鈉注射液
銷售市場：
歐盟非波蘭
規(guī)格：
2,000?IU?(20?mg)/0.2?mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000?IU (120?mg)/0.8?mL 15,000?IU (150?mg)/1?mL 30,000?IU (300?mg)/3?mL 50,000?IU (500?mg)/5?mL 100,000 IU (1000 mg)/10 mL
適應(yīng)癥：
Inhixa is indicated in adults for:

·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

·Acute coronary syndrome:

·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).